✦ LIBER ✦

Information needs of adult patients 50 or older with newly diagnosed acute myeloid leukemia

✍ Scribed by T. Yogaparan; A. Panju; M. Minden; J. Brandwein; H.Z. Mohamedali; S.M.H. Alibhai

Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 169 KB
Volume: 33
Category: Article
ISSN: 0145-2126
DOI: 10.1016/j.leukres.2008.12.008

No coin nor oath required. For personal study only.

✦ Synopsis

When faced with a life-threatening illness such as acute myeloid leukemia (AML), patients may feel overwhelmed with making treatment decisions. We recruited 31 consecutive English-speaking patients aged > or = 50 with newly diagnosed AML. We explored patient information needs, decision-making roles, and perceptions about prognosis. Most patients felt that they had enough information about the diagnosis and treatment options and that the doctor spent the right amount of time with them. The majority of patients preferred a passive or collaborative decision-making role. Almost half the patients did not know their estimated 6-month prognosis, and 17% felt it was 90% or better.

📜 SIMILAR VOLUMES

Financial analysis of patients with newl

Financial analysis of patients with newly diagnosed acute myelogenous leukemia on protocol or standard therapy

✍ Ellin Berman; Claudia Little; Bonnie Teschendorf; Meaghan Jones; Glenn Heller 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB 👁 1 views

## Background: Medicare and third-party payers may be reluctant to pay for investigational (protocol) therapy for patients with cancer on the premise that such treatment is more expensive than standard therapy. however, prior studies that have attempted to compare protocol therapy with standard the

Long-term follow-up of patients with new

Long-term follow-up of patients with newly diagnosed acute myeloid leukemia treated at the University of Texas M. D. Anderson Cancer Center

✍ Elihu Estey; Marcos deLima; Sara Strom; Sherry Pierce; Emil J Freireich; Michael 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB 👁 3 views

## RESULTS. Because failure rates declined to relatively low levels after a first or later complete remission of ¢3 years' duration, such patients comprised a ''potentially Departments of Hematology and Epidemiology, cured'' cohort. The criterion for entry into this cohort was fulfilled by 215 pat

Bone marrow dysplasia in patients with n

Bone marrow dysplasia in patients with newly diagnosed acute myelogenous leukemia does not correlate with history of myelodysplasia or with remission rate and survival

✍ Karen K. Ballen; D. Gary Gilliland; Leslie A. Kalish; Lawrence N. Shulman 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 634 KB

Background. The records and initial bone marrow studies of 106 patients with newly diagnosed acute myelogenous leukemia (AML) were analyzed retrospectively to determine whether bone marrow dysplasia was predictive of a previous myelodysplastic disorder or correlated with remission rate and survival.

A phase 1-2 study of a farnesyltransfera

A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome

✍ Elias Jabbour; Hagop Kantarjian; Farhad Ravandi; Guillermo Garcia-Manero; Zeev E 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 221 KB 👁 1 views

## Abstract ## BACKGROUND: The authors conducted a phase 1/2 study of tipifarnib in combination with idarubicin and cytarabine (IA) in 95 patients with previously untreated acute myeloid leukemia (AML) or high‐risk myelodysplastic syndrome. ## METHODS: Induction consisted of idarubicin 12 mg/m^2

Results of intensive chemotherapy in 998

Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: : Predictive prognostic models for outcome

✍ Hagop Kantarjian; Susan O'Brien; Jorge Cortes; Francis Giles; Stefan Faderl; Eli 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB 👁 1 views

## Abstract ## BACKGROUND Elderly patients (age ≥ 65 years) with acute myeloid leukemia (AML) generally have a poor prognosis. AML‐type therapy results are often derived from studies in younger patients and may not apply to elderly AML. Many investigators and oncologists advocate, at times, only s

Adult patients with acute myeloid leukem

Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis : A report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group

✍ Jacob M. Rowe; Haesook T. Kim; Peter A. Cassileth; Hillard M. Lazarus; Mark R. L 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 360 KB